Use of SERP-1 as an antiplatelet agent

Details Use of SERP-1 as an antiplatelet agent Use of SERP-1 as an antiplatelet agent

2007-09-07

2010-06-29

Carlson, Karen Cochrane (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C435S183000

Reexamination Certificate

active

07745396

ABSTRACT:
Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.

REFERENCES:
patent: 5686409 (1997-11-01), McFadden et al.
patent: 5688824 (1997-11-01), Williams
patent: 5917014 (1999-06-01), McFadden et al.
patent: 5939525 (1999-08-01), McFadden et al.
patent: 7285530 (2007-10-01), Lucas et al.
patent: 7419670 (2008-09-01), Zhong et al.
patent: 7514405 (2009-04-01), Lucas et al.
patent: 2009/0221472 (2009-09-01), Lucas et al.
patent: 0356945 (1993-11-01), None
patent: 0567816 (1993-11-01), None
patent: 0985412 (2000-03-01), None
patent: 1365798 (2002-04-01), None
patent: 0817646 (2003-01-01), None
patent: 1223971 (2005-06-01), None
patent: 2108633 (1990-04-01), None
patent: 6009425 (1994-01-01), None
patent: WO 91/15221 (1991-10-01), None
patent: WO 92/06706 (1992-04-01), None
patent: WO 92/22320 (1992-12-01), None
patent: WO 93/10812 (1993-06-01), None
patent: WO 95/27503 (1995-10-01), None
patent: WO 96/30042 (1996-10-01), None
patent: WO 97/10006 (1997-03-01), None
patent: WO 99/62540 (1999-12-01), None
patent: WO 00/45834 (2000-08-01), None
patent: WO 00/53793 (2000-09-01), None
patent: WO 01/30379 (2001-05-01), None
patent: WO 01/38790 (2001-05-01), None
patent: WO 01/39790 (2001-06-01), None
patent: WO 02/26245 (2002-04-01), None
patent: WO 2004/039391 (2004-05-01), None
Zalia, C. V. et al., “Increased Circulating Monocyte Activation in Patients With Unstable Coronary Syndromes”,Journal of the American College of Cardiology, 38(5):1340-1347 (2001).
Nash, P. et al., “Inhibitory Specificity of the Anti-Inflammatory Myxoma Virus Serpin, SERP-1”,The Journal of Biological Chemistry, 273(33):20982-20991 (1998).
Lomas, D. A. et al., “Inhibition of Plasmin, Urokinase, Tissue Plasminogen Activator, and Cisby a Myxoma Virus Serine Proteinase Inhibitor”,The Journal of Biological Chemistry, 268(1):516-521 (1993).
Lucas, A. et al., “Virus-Encoded Serine Proteinase Inhibitor SERP-1 Inhibits Atherosclerotic Plaque Development After Balloon Angioplasty”,Circulation, 94:2890-2900 (1996).
Lucas, A. et al., “Transplant Vasculopathy: Viral Anti-Inflammatory Serpin Regulation of Atherogenesis”,J. Heart Lung Transplant., 19:1029-1038 (2000).
Miller, L. W. et al., “Inhibition of Transplant Vasculopathy in a Rat Aortic Allograft Model After Infusion of Anti-Inflammatory Viral Serpin”,Circulation, 101:1598-1605 (2000).
Bot, I. et al., “Serine Protease Inhibitor Serp-1 Strongly Impairs Atherosclerotic Lesion Formation and Induces a Stable Plaque Phenotype in ApoE-/-Mice”,Cir. Res., 93:464-471 (2003).
Brahn, E. et al., “Suppression of Collagen-Induced Arthritis With a Serine Proteinase Inhibitor cloned From a Myxoma Viral Sequence”,American College of Rheumatology Meeting, Nov. 13-17, 1999, Abstract.
Bedard, E. et al., “Viral Proteins: A Novel Approach to Preventing Chronic Rejection”,American Society of Transplant Surgeons(2002), Abstract.
Wang, H. et al., “Serp-1, a viral anti-inflammatory serpin, attenuates acute xenograft rejection in a rat-to-mouse cardiac transplant model”,7thInternational Congress of Xenotransplantation(2003), Abstract.
Dai, E. et al., “Serp-1, a Viral Anti-inflammatory Serpin, Regulates Cellular Serine Proteinase and Serpin Responses to Vascular Injury”,The Journal of Biological Chemistry, 278(20):18563-18572 (2003).
Viswanathan, K. et al., “Serpins—A Link Between The Thrombolytic and Innate Immune Response Pathways”,Scientific Session of the American Heart Association Meeting, Nov. 7-10, 2004, Abstract.
Viswanathan, K. et al., “Serpins—A Link Between The Thrombolytic and Innate Immune Response Pathways”,Canadian Cardiovascular Congress, Oct. 23-27, 2004, Abstract.
Viswanathan, K. et al., “The Anti-inflammatory Viral Serpin Serp-1, Inhibits Human Monocyte Cell Activation”,Sixth World Congress on Inflammation Meeting, Aug. 2-6, 2003, Abstract.
Viswanathan, K. et al., “Serp-1, A Viral Anti-Inflammatory and Anti-Atherogenic Protein Sequentially Alters Membrane Fluidity in Activated Human Atherogenic Cells”,Canadian Cardiovascular Congress, Oct. 24-29, 2003, Abstract.
Lucas, A. et al., “Regulation of Vascular Innate Immune Responses by Viral and Mammalian Serpins”,XIII International Vascular Biology Meeting, Jun. 1-5, 2004, Abstract.
Dai, E. et al., “Evaluation of the Effects of Viral Serpin Infusion on Plaque Growth After Aortic Transplant Using PAI-1-/- Mouse Model”,Canadian Cardiovascular Congress, Oct. 24-29, 2003, Abstract.
Dai, E. et al., “Viral Serpin Regulation of Transplant Vasculopathy Development”,Canadian Cardiovascular Congress, Oct. 26-30, 2002, Abstract.
Jiang H. et al., “Characterization and Functional Analysis of 12 Naturally Occurring Reactive Site Variants of Serpin-1 fromManduca Sexta”,The Journal of Biological Chemistry272(2):1082-1087 (1997).
Abraham et al., “Characterization of a Late Phase Pulmonary Response after Antigen Challenge in Allergic Sheep,”Am. Rev. Respir. Dis.128:839-844, 1993.
Abraham et al., “α4-Integrins Mediate Antigen-Induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep,”J. Clin. Invest.93:776-787, 1994.
Aziz et al., “Transplant Arterial Vasculopathy: Evidence for a Dual Pattern of Endothelial Injury and the Source of Smooth Muscle Cells in Lesions of Intimal Hyperplasia,”J. Heart Lung Transplant.14:S123-S136, 1995.
Barsoum, “Introduction of Stable High-Copy-Number DNA into Chinese Hamster Ovary Cells by Electroporation,”DNA Cell. Biol.9:293-300, 1990.
Bédard et al., “Prevention of Chronic Renal Allograft Rejection by SERP-1 Protein,”Transplantation81:908-914, 2006.
Ben-Nun et al., “The Rapid Isolation of Clonable Antigen-Specific T Lymphocyte Lines Capable of Mediating Autoimmune Encephalomyelitis,”Eur. J. Immunol.11:195-199, 1981.
Bowes et al., “Diaspirin Cross-Linked Hemoglobin Improves Neurological Outcome Following Reversible but not Irreversible CNS Ischemia in Rabbits,”Stroke25:2253-2257, 1994.
Burgess et al., “Possible Dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-Binding Activities by Site-Directed Mutagenesis of a Single Lysine Residue,”J. Cell Biol.111:2129-2138, 1990.
Burkly et al., “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigen-4 Integrin,”Diabetes43:529-534, 1994.
Colvin, “CADI,Canti, Cavi,” Transplantation83:677-678, 2007.
Cosimi et al., “In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts,”J. Immunol.144:4604-4612, 1990.
Dai et al., “Reduction of Plaque Development Following Stenting with Viral Inhibitory Proteins Serp-1 and M-T7—a Novel Method of Reducing Post Stenting Restenosis,” Congress of the European Society of Cardiology, Sep. 1-5, 2001, Abstract.
Davis et al., “The Effect of Age on Cerebral Oedema, Cerebral Infarction and Neuroprotective Potential in Experimental Occlusive Stroke,”Acta Neurochir. Suppl.60:282-284, 1994.
Davison and Moss, “New Vaccinia Virus Recombination Plasmids Incorporating a Synthetic Late Promoter for High Level Expression of Foreign Proteins,”Nucl. Acids Res.18:4285-4286, 1990.
Doerschuk et al., “CD18-Dependent and -Independent Mechanisms of

Affiliated with

Also associated with

Rating

Use of SERP-1 as an antiplatelet agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of SERP-1 as an antiplatelet agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of SERP-1 as an antiplatelet agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4216597